首页> 外文OA文献 >Novel brachytherapy techniques for cervical cancer and prostate cancer
【2h】

Novel brachytherapy techniques for cervical cancer and prostate cancer

机译:宫颈癌和前列腺癌的新型近距离放射治疗技术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intensity-modulated brachytherapy techniques, compensator-based intensity modulated brachytherapy (CBT) and interstitial rotating shield brachytherapy (I-RSBT), are two novel conceptual radiation therapies for treating cervical and prostate cancer, respectively. Compared to conventional brachytherapy techniques for treating cervical cancer, CBT can potentially improve the dose conformity to the high-risk clinical target volume (CTV) of the cervix in a less invasive approach. I-RSBT can reduce the dose delivered to the prostate organ at risks (OARs) with the same radiation dose delivered to the prostate CTV. In this work, concepts and prototypes for CBT and I-RSBT were introduced and developed. Preliminary dosimetric measurements were performed for CBT and I-RSBT, respectively.A CBT prototype system was constructed and experimentally validated. A prototype cylindrical compensator with eight octants, each with different thicknesses, was designed. Direct metal laser sintering (DMLS) was used to construct CoCr and Ti compensator prototypes, and a 4-D milling technique was used to construct a Ti compensator prototype. Gafchromic EBT2 films, held by an acrylic quality assurance (QA) phantom, were irradiated to approximately 125 cGy with an electronic brachytherapy (eBT) source for both shielded and unshielded cases. The dose at each point on the films were calculated using a TG-43 calculation model that was modified to account for the presence of a compensator prototype by ray-tracing.With I-RSBT, a multi-pass dose delivery mechanism with prototypes was developed. Dosimetric measurements for a Gd-153 radioisotope was performed to demonstrate that using multiple partially shielded Gd-153 sources for I-RSBT is feasible. A treatment planning model was developed for applying I-RSBT clinically. A custom-built, stainless steel encapsulated 150 mCi Gd-153 capsule with an outer length of 12.8 mm, outer diameter of 2.10 mm, active length of 9.98 mm, and active diameter of 1.53 mm was used. A partially shielded catheter was constructed with a 500 micron platinum shield and a 500 micron aluminum emission window, both with 180° azimuthal coverage. An acrylic phantom was constructed to measure the dose distributions from the shielded catheter in the transverse plane using Gafchromic EBT3 films. Film calibration curves were generated from 50, 70, and 100 kVp x-ray beams with NIST-traceable air kerma values to account for energy variation.In conclusion, CBT, which is a non-invasive alternative to supplementary interstitial brachytherapy, is expected to improve dose conformity to bulky cervical tumors relative to conventional intracavitary brachytherapy. However, at the current stage, it would be time-consuming to construct a patient-specific compensator using DMLS, and the quality assurance of the compensator would be difficult. I-RSBT is a promising approach to reducing radiation dose delivered to prostate OARs. The next step in making Gd-153 based I-RSBT feasible in clinic is developing a Gd-153 source that is small enough such that the source, shield, and catheter all fit within a 16 guage needle, which has a 1.65 mm diameter.
机译:强度调节的近距离放射治疗技术,基于补偿器的强度调制的近距离放射治疗(CBT)和间质旋转屏蔽近距离放射治疗(I-RSBT)是分别用于治疗宫颈癌和前列腺癌的概念性辐射疗法。与用于治疗宫颈癌的常规近距离放射治疗技术相比,CBT可以以较少的侵入方法潜在地改善宫颈的高风险临床目标体积(CTV)的剂量符合。 I-RSBT可以将递送到前列风琴的剂量(OAR)减少到具有递送到前列腺CTV的相同辐射剂量的风险(OAR)。在这项工作中,介绍和开发了CBT和I-RSBT的概念和原型。对CBT和I-RSBT进行了初步的剂量测量。CBT原型系统建成并实验验证。设计了具有八个八个八个八个八个厚度的原型圆柱补偿器,设计。直接金属激光烧结(DMLS)用于构建COCR和TI补偿器原型,并使用4-D铣削技术构建TI补偿器原型。通过丙烯酸质量保证(QA)幻影保持的Gafchromic EBT2薄膜用电子近距离放射治疗(EBT)来源照射到大约125cGy,用于屏蔽和非屏蔽案件。使用TG-43计算模型计算薄膜上的每个点的剂量,该计算模型被修改为通过Ray-Tracing进行补偿器原型的计算。在I-RSBT中,开发了一种具有原型的多通剂量输送机制。进行GD-153放射性同位素的剂量测量以证明使用用于I-RSBT的多个部分屏蔽的GD-153来源是可行的。开发了一种治疗规划模型,用于临床应用I-RSBT。定制的不锈钢封装150mCi GD-153胶囊,外部长度为12.8毫米,外径为2.10毫米,活性长度为9.98mm,使用有效直径为1.53mm。用500微米铂屏蔽和500微米铝排放窗口构建部分屏蔽导管,均具有180°方位角覆盖率。构造丙烯酸模型以使用GafChromic EBT3膜测量横向平面中的屏蔽导管的剂量分布。薄膜校准曲线从50,70和100 kVP X射线束产生,与NIST可追踪的空气Kerma值进行解释,以考虑能量变异。在结论中,预计CBT,这是对补充间质近距离放射治疗的非侵入性替代品的CBT相对于常规颈椎近距离放射治疗,提高剂量符合庞大的宫颈肿瘤。然而,在当前阶段,使用DMLS构建患者特定的补偿器将是耗时的,并且补偿器的质量保证将困难。 I-RSBT是减少辐射剂量递送到前列腺桨的有希望的方法。在临床上制作基于GD-153的I-RSBT的下一步正在开发足够小的GD-153源,使得源极,屏蔽和导管全部适用于直径为1.65mm的165mm。

著录项

  • 作者

    Xing Li;

  • 作者单位
  • 年度 -1
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号